A Study Evaluating the Efficacy and Safety of Obinutuzumab in Participants With Primary Membranous Nephropathy
Public ClinicalTrials.gov record NCT04629248. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase III Randomized, Open-Label Active Comparator-Controlled Multicenter Study to Evaluate Efficacy and Safety of Obinutuzumab in Patients With Primary Membranous Nephropathy
Study identification
- NCT ID
- NCT04629248
- Recruitment status
- Active, not recruiting
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Enrollment
- 142 participants
Conditions and interventions
Conditions
Interventions
- Acetaminophen Drug
- Diphenhydramine Drug
- Methylprednisolone Drug
- Obinutuzumab Drug
- Tacrolimus Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years to 75 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jun 24, 2021
- Primary completion
- Dec 21, 2025
- Completion
- Dec 20, 2027
- Last update posted
- Apr 6, 2026
2021 – 2027
United States locations
- U.S. sites
- 8
- U.S. states
- 8
- U.S. cities
- 8
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Kaiser Permanente - San Francisco Medical Center | San Francisco | California | 94118 | — |
| University of Colorado in Denver-Anschutz Medical Campus | Aurora | Colorado | 80045 | — |
| Accel Research Sites; Mid-Florida Kidney and Hypertension Care | Altamonte Springs | Florida | 32701 | — |
| University of Iowa | Iowa City | Iowa | 52242 | — |
| Henry Ford Hospital | Detroit | Michigan | 48202 | — |
| Mayo Clinic | Rochester | Minnesota | 55902 | — |
| Columbia University Medical Center | New York | New York | 10032 | — |
| Nephrotex Research Group | Dallas | Texas | 75231 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 42 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT04629248, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Apr 6, 2026 · Synced May 8, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT04629248 live on ClinicalTrials.gov.